Výsledky vyhledávání - "Almudena Tercero"

Akademický článek

First‐in‐human study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of ALPN‐101, a dual CD28/ICOS antagonist, in healthy adult subjects

Autor: Jing Yang, Jason D. Lickliter, Jan L. Hillson, Gary D. Means, Russell J. Sanderson, Kay Carley, Almudena Tercero, Kristi L. Manjarrez, Jennifer R. Wiley, Stanford L. Peng

Publikováno v: Clinical and Translational Science, Vol 14, Iss 4, Pp 1314-1326 (2021)

Abstract ALPN‐101 (ICOSL vIgD‐Fc) is an Fc fusion protein of a human inducible T cell costimulatory ligand (ICOSL) variant immunoglobulin domain (vIgD) designed to inhibit the cluster of differentiation 28 (CD28) and inducible T cell costimulator

Externí odkaz: https://doaj.org/article/701f4101ee394f428fca2532c07f1b57

Zobrazit plný text záznamu

Plný text ve formátu HTML

Abstract 10 Interim Results of a Phase I Study Investigating a Cord Blood-Derived Natural Killer Cell Therapy for Patients Hospitalized with COVID-19

Autor: Almudena Tercero, Dan Finlay, Liya H Asghedom, Gladys R Romasanta, Natalie T Rice, Fatima Ranjbaran, Carrie Stoltzman, Jody Cook, Joe Blake, Colleen Delaney, Joshua A Hill

Publikováno v: Stem Cells Translational Medicine. 11:S12-S12

Introduction In the setting of viral infections, including infection with SARS-CoV-2, lymphocyte exhaustion and lymphopenia are common. Patients with COVID-19 who develop lymphopenia, particularly low numbers of circulating natural killer (NK) cells,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::580ae2de0cb0f020464cc99ee6d03247
https://doi.org/10.1093/stcltm/szac057.010

Zobrazit plný text záznamu

First-in-human study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of ALPN-101, a dual CD28/ICOS antagonist, in healthy adult subjects

Autor: Jennifer R. Wiley, Jing Yang, Gary Means, Stanford L. Peng, Jason D. Lickliter, Kay Carley, Russell J. Sanderson, Jan Hillson, Kristi Manjarrez, Almudena Tercero

Publikováno v: Clinical and Translational Science
Clinical and Translational Science, Vol 14, Iss 4, Pp 1314-1326 (2021)

ALPN‐101 (ICOSL vIgD‐Fc) is an Fc fusion protein of a human inducible T cell costimulatory ligand (ICOSL) variant immunoglobulin domain (vIgD) designed to inhibit the cluster of differentiation 28 (CD28) and inducible T cell costimulator (ICOS) p

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::061513295bba9dfd47595f6cac8f4cdf
https://pubmed.ncbi.nlm.nih.gov/33503289

Zobrazit plný text záznamu

Abstract CT213: NEON-1: a first-in-human phase I open-label study of ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor, in advanced malignancies

Autor: Wael A. Harb, Jing Yang, Diwakar Davar, Justin C. Moser, Gary Means, Hany Zayed, Almudena Tercero, Kristi Manjarrez, Stanford L. Peng, Graciela Noemi Perez, Jan Hillson, Christine Dela Cruz, Michael Millward, Mark Voskoboynik, Nehal Lakhani

Publikováno v: Cancer Research. 81:CT213-CT213

BACKGROUND: Checkpoint inhibitors (CPI) targeting the PD-1 and CTLA-4 pathways have demonstrated significant clinical benefit in multiple tumors, but the majority of patients exhibit or develop resistance, at least in part due to insufficient activat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::09811f595a6032d6479237e1b4bee1ee
https://doi.org/10.1158/1538-7445.am2021-ct213

Zobrazit plný text záznamu

First-in-human dose escalation of ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor, in advanced malignancies

Autor: Jing Yang, Mark Voskoboynik, Justin C. Moser, Diwakar Davar, Michael Millward, Christine Dela Cruz, Kristi Manjarrez, Stanford L. Peng, Wael A. Harb, Graciela Noemi Perez, Jan Hillson, Gary Means, Nehal Lakhani, Almudena Tercero, Hany Zayed

Publikováno v: Journal of Clinical Oncology. 39:2547-2547

2547 Background: Strong preclinical rationale has emerged for combining checkpoint inhibition (CPI) with T cell costimulatory agonists, particularly CD28, a critical T cell costimulatory molecule recently recognized as a key target of checkpoint inhi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::2737c48b24bfcdce0bfc6e46faee3a03
https://doi.org/10.1200/jco.2021.39.15_suppl.2547

Zobrazit plný text záznamu

Abstract CT245: NEON-1: A first-in-human phase I open-label study of ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor, in advanced malignancies

Autor: Stanford L. Peng, Kristi Manjarrez, Jing Yang, Almudena Tercero, Jan Hillson, Gary Means

Publikováno v: Cancer Research. 80:CT245-CT245

Background: Checkpoint inhibitors (CPI) targeting the PD-(L)1 and CTLA-4 pathways have demonstrated significant clinical benefit in many cancers, but the majority of patients unfortunately still fail to demonstrate objective responses and/or develop

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1ecf37b134c795958f5192d452543151
https://doi.org/10.1158/1538-7445.am2020-ct245

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání